Vincent Rajkumar
@VincentRK
Editor-in-Chief, Blood Cancer Journal; Oncologist; Cancer Research; Opinions are solely my personal views https://t.co/HOGYJSpsoG
ID:24261916
https://vincentrk.com 13-03-2009 21:46:06
51,9K Tweets
80,8K Followers
1,5K Following
Follow People
Nico Gagelmann
@TheEBMT_Trainee co-chair. Hematology. Medicine. Science. Train. Think. Implement an integral actuality.
Amer Zeidan MBBS,MHS عامر زيدان
Associate Prof, Director #Leukemia Prog; A/Director Heme CTO & early therapy research @Yale. @ic_MDS Personal/own opinions. COI https://t.co/6XkF8CmtrK
Mohamad Mohty
Professor and head of Hematology Sorbonne Univ.; past-president of the EBMT; Chairman of the IACH; Editor in Chief: Bone Marrow Transplant; Clin Hematol Int.
Manni Mohyuddin
Cancer doctor with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. Views own.
David Steensma, MD
Hematologist-oncologist. @AjaxThx CMO. Former Edward P. Evans Chair in MDS @DanaFarber, @HarvardMed & @MayoClinic faculty, @NovartisScience hematology head.
Twitter Spaces on myeloma in 10 minutes. With Yelak Biru
International Myeloma Foundation
Updates in myeloma and answer your questions. Spaces #IMFmyelomaChat
cc: Mike Thompson, MD, PhD, FASCO Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Nikhil C. Munshi, MD Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽
This is the landing page for the International Myeloma Working Group (IMWG) It has links to all IMWG publications and all our committees. Bookmark it!
International Myeloma Foundation myeloma.org/international-…
Join us today at 730pm eastern on Twitter Spaces where we will discuss updates in myeloma and answer your questions. Spaces #IMFmyelomaChat
This is going to be part of International Myeloma Foundation initiative featuring IMF CEO Yelak Biru
Dr Vincent Rajkumar kicking of the spring ECOG-ACRIN Cancer Research Group meeting with a reminder of the Scientific Objectives of the myeloma committee. #eaonc Mike Thompson, MD, PhD, FASCO Natalie Callander
In Baltimore for ECOG-ACRIN Cancer Research Group Spring Meeting.
Myeloma committee meets today. Look forward to good discussion on future trials.
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] Vincent Rajkumar et al. The Lancet Oncology ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
![Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm](https://pbs.twimg.com/media/GMfKU9KWYAEvYGO.jpg "Mike Thompson, MD, PhD, FASCO (@mtmdphd) on Twitter photo 2024-05-01 10:32:30 Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm")
Just out: International Myeloma Working Group guidelines for bispecific antibodies myeloma.
Limited time: Free copy link in the thread. The Lancet Oncology Paula Rodriguez-Otero Jonathan Kaufman, MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Yi Lin Tom Martin marivi mateos Ben Derman Monique Minnema et al thelancet.com/journals/lanon…
